File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning

TitleClinical prediction of HBV and HCV related hepatic fibrosis using machine learning
Authors
KeywordsFIB-4
Gradient boosting
Hepatic fibrosis
Hepatitis B
Hepatitis C
Machine learning
Issue Date2018
Citation
EBioMedicine, 2018, v. 35, p. 124-132 How to Cite?
AbstractClinical prediction of advanced hepatic fibrosis (HF) and cirrhosis has long been challenging due to the gold standard, liver biopsy, being an invasive approach with certain limitations. Less invasive blood test tandem with a cutting-edge machine learning algorithm shows promising diagnostic potential. In this study, we constructed and compared machine learning methods with the FIB-4 score in a discovery dataset (n = 490) of hepatitis B virus (HBV) patients. Models were validated in an independent HBV dataset (n = 86). We further employed these models on two independent hepatitis C virus (HCV) datasets (n = 254 and 230) to examine their applicability. In the discovery data, gradient boosting (GB) stably outperformed other methods as well as FIB-4 scores (p <.001) in the prediction of advanced HF and cirrhosis. In the HBV validation dataset, for classification between early and advanced HF, the area under receiver operating characteristic curves (AUROC) of GB model was 0.918, while FIB-4 was 0.841; for classification between non-cirrhosis and cirrhosis, GB showed AUROC of 0.871, while FIB-4 was 0.830. Additionally, GB-based prediction demonstrated good classification capacity on two HCV datasets while higher cutoffs for both GB and FIB-4 scores were required to achieve comparable specificity and sensitivity. Using the same parameters as FIB-4, the GB-based prediction system demonstrated steady improvements relative to FIB-4 in HBV and HCV cohorts with different cutoff values required in different etiological groups. A user-friendly web tool, LiveBoost, makes our prediction models freely accessible for further clinical studies and applications.
Persistent Identifierhttp://hdl.handle.net/10722/342573
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWei, Runmin-
dc.contributor.authorWang, Jingye-
dc.contributor.authorWang, Xiaoning-
dc.contributor.authorXie, Guoxiang-
dc.contributor.authorWang, Yixing-
dc.contributor.authorZhang, Hua-
dc.contributor.authorPeng, Cheng Yuan-
dc.contributor.authorRajani, Cynthia-
dc.contributor.authorKwee, Sandi-
dc.contributor.authorLiu, Ping-
dc.contributor.authorJia, Wei-
dc.date.accessioned2024-04-17T07:04:45Z-
dc.date.available2024-04-17T07:04:45Z-
dc.date.issued2018-
dc.identifier.citationEBioMedicine, 2018, v. 35, p. 124-132-
dc.identifier.urihttp://hdl.handle.net/10722/342573-
dc.description.abstractClinical prediction of advanced hepatic fibrosis (HF) and cirrhosis has long been challenging due to the gold standard, liver biopsy, being an invasive approach with certain limitations. Less invasive blood test tandem with a cutting-edge machine learning algorithm shows promising diagnostic potential. In this study, we constructed and compared machine learning methods with the FIB-4 score in a discovery dataset (n = 490) of hepatitis B virus (HBV) patients. Models were validated in an independent HBV dataset (n = 86). We further employed these models on two independent hepatitis C virus (HCV) datasets (n = 254 and 230) to examine their applicability. In the discovery data, gradient boosting (GB) stably outperformed other methods as well as FIB-4 scores (p <.001) in the prediction of advanced HF and cirrhosis. In the HBV validation dataset, for classification between early and advanced HF, the area under receiver operating characteristic curves (AUROC) of GB model was 0.918, while FIB-4 was 0.841; for classification between non-cirrhosis and cirrhosis, GB showed AUROC of 0.871, while FIB-4 was 0.830. Additionally, GB-based prediction demonstrated good classification capacity on two HCV datasets while higher cutoffs for both GB and FIB-4 scores were required to achieve comparable specificity and sensitivity. Using the same parameters as FIB-4, the GB-based prediction system demonstrated steady improvements relative to FIB-4 in HBV and HCV cohorts with different cutoff values required in different etiological groups. A user-friendly web tool, LiveBoost, makes our prediction models freely accessible for further clinical studies and applications.-
dc.languageeng-
dc.relation.ispartofEBioMedicine-
dc.subjectFIB-4-
dc.subjectGradient boosting-
dc.subjectHepatic fibrosis-
dc.subjectHepatitis B-
dc.subjectHepatitis C-
dc.subjectMachine learning-
dc.titleClinical prediction of HBV and HCV related hepatic fibrosis using machine learning-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ebiom.2018.07.041-
dc.identifier.pmid30100397-
dc.identifier.scopuseid_2-s2.0-85051120305-
dc.identifier.volume35-
dc.identifier.spage124-
dc.identifier.epage132-
dc.identifier.eissn2352-3964-
dc.identifier.isiWOS:000445436400026-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats